Current and novel immunosuppressive therapy for autoimmune hepatitis

Hepatology

Volumn 35, Issue 1, 2002, Pages 7-13

  Heneghan, Michael A ^a   McFarlane, Ian G ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEFLAZACORT; FINGOLIMOD; HLA B8 ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PREDNISOLONE; PREDNISONE; T LYMPHOCYTE RECEPTOR; TACROLIMUS; THIOGUANINE DERIVATIVE; URSODEOXYCHOLIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CYTOPENIA; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MOON FACE; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; SIDE EFFECT; TREATMENT INDICATION;

EID: 0036137543     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.30991     Document Type: Article

References (50)

1. International Autoimmune Hepatitis Group report: Review of criteria for diagnosis of autoimmune hepatitis
2. Autoimmune hepatitis in childhood: A 20-year experience
3. Susceptibility to autoimmune chronic active hepatitis: Human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors
4. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis
5. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis
6. Effect of prednisone on the survival of patients with cirrhosis of the liver
7. Controlled prospective trial of corticosteroid therapy in chronic active hepatitis
8. Clinical, biochemical, and histological remission of severe chronic active liver disease: A controlled study of treatments and early prognosis
9. Controlled trial of prednisone and azathioprine in active chronic hepatitis
10. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis
11. Short-term cyclosporine induces a remission of autoimmune hepatitis in children
12. Low dose tacrolimus as treatment of severe autoimmune hepatitis: Potential role in remission induction
13. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis
14. Survival and histological resolution of fibrosis in patients with autoimmune chronic active hepatitis
15. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis
16. Duration of immunosuppressive therapy in autoimmune hepatitis
17. The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis
18. Late results ofthe Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis
19. Autoimmune hepatitis
20. The long-term pathological evolution of chronic hepatitis C
21. Diagnostic criteria, clinical manifestations and natural history of autoimmune hepatitis
22. Management and outcome of pregnancy in autoimmune hepatitis
23. Immunosuppressive drug mechanisms
24. Treatment of autoimmune hepatitis
25. Reversibility of hepatic fibrosis in autoimmune hepatitis
26. Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy
27. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis
28. Randomised controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis
29. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal
30. Azathioprine for long-term maintenance of remission in autoimmune hepatitis
31. Autoimmune hepatitis and its variant syndromes
32. Clinical implications of thiopurine methyltransferase-optimization of drug dosage and potential drug interactions
33. A case of cyclosporine-sensitive, steroid-resistant, autoimmune chronic active hepatitis
34. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis
35. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis
36. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis
37. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis
38. Tacrolimus: A potential new treatment for autoimmune chronic active hepatitis: Results of an open-label preliminary trial
39. Oral budesonide for treatment of autoimmune chronic active hepatitis
40. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis
41. Deflazacort for long-term maintenance of remission in type 1 autoimmune hepatitis
42. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine
43. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis-report of three cases
44. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate
45. Treatment of primary biliary cirrhosis
46. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis
47. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: A randomized placebo-controlled treatment trial
48. Controlled trial of synthetic D-penicillamine and prednisone in maintenance therapy for active chronic hepatitis
49. D-penicillamine therapy in patients with HBsAg-negative chronic active hepatitis and major prednisolone-induced adverse effects
50. A novel immunosuppressant, FTY720, increases the efficiency of a superantigen-induced peripheral T cell deletion whilst inhibiting negative selection in the thymus